Dados B3 › JALL3 × BRFS3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | JALL3 | BRFS3 | year |
|---|---|---|---|
| ROE | 0.0% | 23.2% | 2025 |
| ROIC | 6.0%! | 19.5% | 2025 |
| ROA | -0.8% | 5.0% | 2025 |
| Gross margin | 27.3% | 25.2% | 2025 |
| EBIT margin | 20.2% | 10.2% | 2025 |
| Net margin | -2.4% | 5.1% | 2025 |
| Net debt/EBITDA | 2.16x | 1.42x | 2025 |
| Current ratio | 2.19x | 1.36x | 2025 |
| Revenue growth (1y) | 22.4% | 6.0% | 2025 |
| Revenue growth (5y CAGR) | 21.3% | 10.5% | 2025 |
| Piotroski F-Score | 5/9 | 4/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | JALL3 | BRFS3 | year |
|---|---|---|---|
| P/E | 75.58x | 9.59x | 2026 × 2024 |
| P/B | 0.36x | 2.04x | 2026 × 2024 |
| EV/EBITDA | 3.91x | 3.81x | 2026 × 2024 |
| FCF yield | 64.0% | 31.8% | 2026 × 2024 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:11 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it